Market Place
Sourcing Support
FDA Confirms Paragraph IV Patent Litigation for Fostamatinib Disodium
13 Jun 2022 //
FDA
Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial
29 Jun 2021 //
PR NEWSWIRE
Rigel’s fostamatinib meets primary endpoint in Covid-19 clinical trial
14 Apr 2021 //
CLINCALTRIALSARENA
Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety
13 Apr 2021 //
RIGEL
Rigel concludes subject enrolment in NIH-sponsored Covid-19 trial
12 Mar 2021 //
CLINICALTRIALSARENA
Rigel and Medison Announce Health Canada Approval of TAVALISSE®
23 Nov 2020 //
PRNEWSWIRE
Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in COVID-19 Patients
17 Sep 2020 //
BIOSPACE
Rigel Announces Conference Call and Webcast to Report Second Quarter 20
27 Jul 2020 //
PRNEWSWIRE
Rigel Announces Availability of TAVLESSE® (Fostamatinib Disodium Hexahydrate)
09 Jul 2020 //
PRNEWSWIRE
Rigel Announces Availability of TAVLESSE® (Fostamatinib Disodium Hexahydrate)
09 Jul 2020 //
PRNEWSWIRE
Rigel to Present Poster Highlighting TAVALISSE at the Virtual Edition the 25th
10 Jun 2020 //
PRNEWSWIRE
Rigel to Present at the Jefferies Virtual Healthcare Conference
26 May 2020 //
PR NEWSWIRE
Rigel Receive Positive Trend Vote from CHMP for Fostamatinib Disod. Hexahydrate
18 Oct 2019 //
PR NEWSWIRE
Sobi finds another fit for its dealmaking strategy
01 Oct 2019 //
BIOPHARMADIVE
Rigel Pharm License Agreement to Commercialize fostamatinib disodium hexahydrate
29 Oct 2018 //
PR NEWSWIRE
Rigel Receives EMA Validation of Appln for Fostamatinib Disodium Hexahydrate
11 Oct 2018 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.